<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644731</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN07423</org_study_id>
    <nct_id>NCT04644731</nct_id>
  </id_info>
  <brief_title>Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)</brief_title>
  <acronym>ULTRA-Peds</acronym>
  <official_title>ULTRA-Peds: A Multicenter Data Registry for Outcomes for Pediatric Volume Overload</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuwellis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AKI Critical Care Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nuwellis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The ULTRA-Peds registry will employ a multi-center, single-arm, open-label, observational&#xD;
      design to capture baseline, procedural and follow-up data on pediatric patients that have&#xD;
      been treated (i.e., retrospective data from treatment at the time of registry approval by the&#xD;
      IRB) or are scheduled to be treated (i.e., prospective data for on-label treatment after&#xD;
      registry approval by the IRB) with Aquadex therapy according to local standard of care&#xD;
      practices and decisions. All prospective data will be from on-label Aquadex treatment of&#xD;
      pediatric patients weighing 20 kilograms or more. No data from prospective off-label&#xD;
      treatment (i.e., Aquadex treatment with other adjunctive or conjunctive therapies for&#xD;
      pediatric patients who may weigh less than 20kg) will be included in the registry. An&#xD;
      estimated 10 sites in the United States who have received training in extracorporeal therapy&#xD;
      and the Aquadex™ system will enroll a minimum of 500 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ULTRA-PEDs registry is designed to capture data in the real-World clinical setting on the&#xD;
      Aquadex™ system in local standard of care, with the aim of understanding it's performance and&#xD;
      utilization. Enrollment is expected to take approximately 2.5 years from the time the first&#xD;
      patient is enrolled to the time the final patient is discharged from the hospital.&#xD;
&#xD;
      ULTRA-PEDs will allow prospective and retrospective data collection for the following&#xD;
      scenarios:&#xD;
&#xD;
        -  All prospective data for on-label use only (i.e., Aquadex ultrafiltration therapy for&#xD;
           pediatric patients weighing 20 kg or more, whose fluid overload is unresponsive to&#xD;
           medical management, including diuretics).&#xD;
&#xD;
        -  Retrospective patients at the time of registry approval by IRB regardless of on-label or&#xD;
           off-label use.&#xD;
&#xD;
             -  Retrospective on-label use&#xD;
&#xD;
             -  Retrospective off-label use (i.e., Aquadex ultrafiltration with other adjunctive or&#xD;
                conjunctive therapies for pediatric patients who may weigh less than 20kg)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">December 29, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>90 Days</target_duration>
  <primary_outcome>
    <measure>Treatment Survival</measure>
    <time_frame>Through completion of a treatment course, up to 3 months</time_frame>
    <description>Patient survive treatment course</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Survival at ICU discharge</measure>
    <time_frame>Through completion of a treatment course in the ICU, up to 1 month</time_frame>
    <description>% of ICU patients survive treatment in ICU</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Kidney Function</measure>
    <time_frame>Change eGFR and renal labs from initiation to completion of treatment, up to 3 months</time_frame>
    <description>Assessment of Kidney function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic stability at initiation of UF therapy</measure>
    <time_frame>From the time of index procedure is initiated up to 60 minutes after initiation</time_frame>
    <description>Need resuscitation fluids and medications (e.g. vasoactive medication)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodynamic stability during treatment course</measure>
    <time_frame>Through completion of a treatment course, up to 3 months</time_frame>
    <description>Need for vasoactive medication</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change % fluid overload during treatment course</measure>
    <time_frame>Through completion of a treatment course, up to 3 months</time_frame>
    <description>% change in weight from initiation to the end of the last Aquadex procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Length of Stay in ICU</measure>
    <time_frame>The time from admission to ICU through discharge from ICU, usually 1 month</time_frame>
    <description>Time of admission to ICU to discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in PRISM III Score</measure>
    <time_frame>2 hours before ICU admission through the first 4 hours after ICU discharge</time_frame>
    <description>Physiologic variables and labs to assess mortality risk</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Aquadex related adverse events</measure>
    <time_frame>Through completion of a treatment course, up to 3 months</time_frame>
    <description>Aquadex related adverse events</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Pediatric patients who require fluid removal</arm_group_label>
    <description>Pediatric patients who require fluid removal with the Aquadex™ System per local standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aquadex™ System</intervention_name>
    <description>Ultrafiltration for fluid removal</description>
    <arm_group_label>Pediatric patients who require fluid removal</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients who require fluid removal with the Aquadex™ System per local standard of&#xD;
        care&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        I. For enrollment in prospective data collection:&#xD;
&#xD;
          1. Patient age is 21 years or younger&#xD;
&#xD;
          2. Patient weighs 20 kilograms or more.&#xD;
&#xD;
          3. Patient or legally authorized representative provides written authorization or patient&#xD;
             is hospitalized and receiving treatment in a center with an Institutional Review Board&#xD;
             that has allowed for waived consent based on the type of data being collected for the&#xD;
             Registry.&#xD;
&#xD;
          4. Patient is to undergo Aquadex therapy for fluid overload (i.e., fluid removal) as&#xD;
             local standard of care.&#xD;
&#xD;
        II. For enrollment in retrospective data collection:&#xD;
&#xD;
          1. Patient age is 21 years or younger.&#xD;
&#xD;
          2. Patient or legally authorized representative provides written authorization or patient&#xD;
             is hospitalized and receiving treatment in a center with an Institutional Review Board&#xD;
             that has allowed for waived consent based on the type of data being collected for the&#xD;
             Registry.&#xD;
&#xD;
          3. Patient underwent Aquadex therapy for fluid overload (i.e., fluid removal) as local&#xD;
             standard of care.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable or unwilling to provide informed consent&#xD;
&#xD;
          2. Unable or unwilling to comply with study requirements&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart Goldstein, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AKI Critical Care Research Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pei Gbatu, PhD</last_name>
    <phone>9526575822</phone>
    <phone_ext>9526575822</phone_ext>
    <email>pei.gbatu@nuwellis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Children's of Alabama Hospital</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Joe DiMaggio Children's Hospital</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shina Menon, MD</last_name>
      <phone>206-987-5534</phone>
      <email>shina.menon@seattlechildrens.org</email>
    </contact>
    <contact_backup>
      <last_name>Megan Kelton</last_name>
      <phone>206 987 5539</phone>
      <email>Megan.Kelton@seattlechildrens.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

